肠道微生物组模式影响初级胆道胆炎治疗反应
Qiaoyan Liu1, Bingyuan Huang1, Yijun Zhou2
1Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
在一次性胆道胆道炎 (PBC) 中,肠道微生物群的亚型预测了对乌尔索氧胆酸 (UDCA) 的反应. 克洛斯特里迪亚低PBC患者的非响应率较高,表明需要个性化治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 微生物组研究 微生物组研究
背景情况:
- 初级胆道胆炎 (PBC) 是一种渐进的自身免疫性肝脏疾病.
- 对 Ursodeoxycholic 酸 (UDCA) 的不充分反应是疾病进展的重要危险因素.
- 肠道失生症越来越多地被认为是PBC病变发生的一个因素.
研究的目的:
- 为了确定PBC患者风险分层的微生物特征.
- 研究肠道微生物组在PBC中的机械作用.
- 探索PBC的潜在新型治疗点.
主要方法:
- 预期招募 UDCA 治疗前的 PBC 患者 (n=132).
- 便和血清样本的元基因组测序和代谢分析.
- 无监督机器学习用于独立队列中的微生物组亚型识别和验证.
主要成果:
- 基线PBC转基因组分为两个亚型:Clostridia高和Clostridia低.
- 克洛斯特里迪亚低的亚型显示UDCA非响应率高出2倍 (41%对20%).
- 在Clostridia-low亚型中减少了无氧发酵和生物活性代谢物 (基衍生物,二次胆酸) 的产生.
结论:
- 基线肠道微生物组模式可以预测PBC中UDCA治疗结果.
- 基于微生物组的风险分层可能使PBC的个性化治疗策略成为可能.
- 准肠道微生物失调症可能为PBC提供新的治疗途径.
相关概念视频
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents


